High-risk Multiple Myeloma: Definition and Management
Nisha S Joseph1, Silvia Gentili2, Jonathan L Kaufman1
1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Clinical Lymphoma, Myeloma & Leukemia
|August 2, 2017
Summary
Novel therapies improve multiple myeloma prognosis, but high-risk patients with specific genetic factors still face challenges. Future research aims to enhance treatment strategies for better outcomes in this group.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma prognosis has improved with immunomodulation and proteasome inhibitors.
- High-dose therapy and autologous stem cell transplantation enhance responses and survival.
- Novel therapies show limited benefit for patients with high-risk genetic features like del17p, t(14;16), or t(14;20).
Purpose of the Study:
- To identify genetically defined high-risk multiple myeloma patients.
- To describe optimal combination strategies for long-term benefits in high-risk myeloma.
Main Methods:
- Review of clinical evidence on novel antimyeloma agents.
- Analysis of prognostic impact of genetic abnormalities in multiple myeloma.
- Evaluation of combination therapy outcomes in high-risk myeloma subsets.
Main Results:
- Novel therapies mitigate some traditional poor prognostic factors but not all.
- Patients with specific chromosomal abnormalities or plasma cell leukemia have less evident benefits.
- Genomic instability in high-risk myeloma contributes to therapeutic resistance.
Conclusions:
- Understanding high-risk myeloma biology is crucial for targeted therapies.
- Optimizing combination strategies is essential for improving outcomes in high-risk patients.
- Future treatments focusing on genomic instability may enhance prognosis for this subset.
More Related Videos
Related Concept Videos
01:22Myocarditis IV: Nursing Management
286
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
286
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
648
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
648
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K